Brown Brothers Harriman & CO Abb Vie Inc. Transaction History

Brown Brothers Harriman & CO

$14 Billion
Q3 2024

A detailed history of Brown Brothers Harriman & CO transactions in Abb Vie Inc. stock. As of the latest transaction made, Brown Brothers Harriman & CO holds 88,786 shares of ABBV stock, worth $16.1 Million. This represents 0.12% of its overall portfolio holdings.

Number of Shares

88,786

Previous 86,604 2.52%

Holding current value

$16.1 Million

Previous $14.9 Million 18.04%

% of portfolio

0.12%

Previous 0.12%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$163.84 - $199.33 $357,498 - $434,938	2,182 Added 2.52%	88,786 $17.5 Million
Q2 2024 Aug 09, 2024	SELL	$154.79 - $180.76 $555,386 - $648,566	-3,588 Reduced 3.98%	86,604 $14.9 Million
Q1 2024 May 10, 2024	SELL	$159.82 - $182.1 $152,947 - $174,269	-957 Reduced 1.05%	90,192 $16.4 Million
Q4 2023 Feb 12, 2024	SELL	$137.6 - $154.97 $1.25 Million - $1.41 Million	-9,070 Reduced 9.05%	91,149 $14.1 Million
Q3 2023 Nov 13, 2023	BUY	$133.59 - $154.65 $639,495 - $740,309	4,787 Added 5.02%	100,219 $14.9 Million
Q2 2023 Aug 07, 2023	SELL	$132.51 - $164.9 $147,351 - $183,368	-1,112 Reduced 1.15%	95,432 $12.9 Million
Q1 2023 May 11, 2023	BUY	$144.61 - $166.54 $257,550 - $296,607	1,781 Added 1.88%	96,544 $15.4 Million
Q4 2022 Feb 09, 2023	BUY	$138.31 - $165.87 $392,938 - $471,236	2,841 Added 3.09%	94,763 $15.3 Million
Q3 2022 Nov 10, 2022	BUY	$134.21 - $153.93 $361,695 - $414,841	2,695 Added 3.02%	91,922 $12.3 Million
Q2 2022 Aug 11, 2022	BUY	$137.62 - $174.96 $282,121 - $358,668	2,050 Added 2.35%	89,227 $13.7 Million
Q1 2022 May 13, 2022	BUY	$131.98 - $163.75 $663,595 - $823,335	5,028 Added 6.12%	87,177 $14.1 Million
Q4 2021 Feb 14, 2022	BUY	$107.43 - $135.93 $1.52 Million - $1.93 Million	14,190 Added 20.88%	82,149 $11.1 Million
Q3 2021 Nov 15, 2021	BUY	$106.4 - $120.78 $203,862 - $231,414	1,916 Added 2.9%	67,959 $7.33 Million
Q2 2021 Aug 13, 2021	SELL	$105.21 - $117.21 $78,802 - $87,790	-749 Reduced 1.12%	66,043 $7.44 Million
Q1 2021 May 13, 2021	BUY	$102.3 - $112.62 $178,922 - $196,972	1,749 Added 2.69%	66,792 $7.23 Million
Q4 2020 Feb 16, 2021	SELL	$80.49 - $108.67 $615,989 - $831,651	-7,653 Reduced 10.53%	65,043 $6.97 Million
Q3 2020 Nov 16, 2020	BUY	$85.91 - $100.83 $311,767 - $365,912	3,629 Added 5.25%	72,696 $6.37 Million
Q2 2020 Aug 13, 2020	BUY	$73.37 - $98.18 $216,074 - $289,140	2,945 Added 4.45%	69,067 $6.78 Million
Q1 2020 May 15, 2020	BUY	$64.5 - $97.79 $502,068 - $761,197	7,784 Added 13.34%	66,122 $5.04 Million
Q4 2019 Feb 14, 2020	SELL	$72.13 - $90.25 $318,598 - $398,634	-4,417 Reduced 7.04%	58,338 $5.17 Million
Q3 2019 Nov 14, 2019	SELL	$62.98 - $75.72 $212,242 - $255,176	-3,370 Reduced 5.1%	62,755 $4.75 Million
Q2 2019 Aug 14, 2019	SELL	$65.7 - $83.98 $87,315 - $111,609	-1,329 Reduced 1.97%	66,125 $4.81 Million
Q1 2019 May 15, 2019	BUY	$77.14 - $90.79 $339,801 - $399,929	4,405 Added 6.99%	67,454 $5.44 Million
Q4 2018 Feb 14, 2019	SELL	$77.85 - $96.01 $62,357 - $76,904	-801 Reduced 1.25%	63,049 $5.81 Million
Q3 2018 Nov 14, 2018	BUY	$88.91 - $98.84 $589,651 - $655,506	6,632 Added 11.59%	63,850 $6.04 Million
Q2 2018 Aug 14, 2018	SELL	$89.78 - $106.23 $316,205 - $374,142	-3,522 Reduced 5.8%	57,218 $5.3 Million
Q1 2018 May 14, 2018	SELL	$92.01 - $123.21 $175,463 - $234,961	-1,907 Reduced 3.04%	60,740 $5.75 Million
Q4 2017 Feb 14, 2018	BUY	$89.56 - $98.21 $315,609 - $346,092	3,524 Added 5.96%	62,647 $6.06 Million
Q3 2017 Nov 14, 2017	SELL	$69.85 - $89.22 $68,453 - $87,435	-980 Reduced 1.63%	59,123 $5.25 Million
Q2 2017 Aug 14, 2017	BUY	N/A	60,103	60,103 $4.36 Million

Others Institutions Holding ABBV

# of Institutions

3,849

Shares Held

1.25B

Call Options Held

16.8M

Put Options Held

12.2M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $320B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Brown Brothers Harriman & CO, based on Form 13F filings with the SEC.

News

Stay updated on Brown Brothers Harriman & CO with notifications on news.

Account

Brown Brothers Harriman & CO Abb Vie Inc. Transaction History